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Abstract
In older individuals, pulmonary artery pressure rises markedly during exercise,
probably due in part to increased pulmonary vascular resistance and in part
to an increase in left-heart filling pressure. Older individuals also show more
marked pulmonary vascular response to hypoxia at rest. Treatment with intra-
venous iron reduces the rise in pulmonary artery pressure observed during
hypoxia. Here, we test the hypothesis that intravenous iron administration
may also attenuate the rise in pulmonary artery pressure with exercise in older
individuals. In a randomized double-blind placebo-controlled physiology
study in 32 healthy participants aged 50–80 years, we explored the hypothesis
that iron administration would deliver a fall in systolic pulmonary artery pres-
sure (SPAP) during moderate cycling exercise (20 min duration; increase in
heart rate of 30 min1) and a change in maximal cycling exercise capacity
( _VO2max). Participants were studied before, and at 3 h to 8 weeks after, infu-
sion. SPAP was measured using Doppler echocardiography. Iron administra-
tion resulted in marked changes in indices of iron homeostasis over 8 weeks,
but no significant change in hemoglobin concentration or inflammatory
markers. Resting SPAP was also unchanged, but SPAP during exercise was
lower by ~3 mmHg in those receiving iron (P < 0.0001). This effect persisted
for 8 weeks. Although _VO2max remained unaffected in the iron-replete healthy
participants studied here, this study demonstrates for the first time the ability
of intravenous iron supplementation to reduce systolic pulmonary artery pres-
sure during exercise.
Introduction
Increasing age is associated with a reduction in exercise
capacity. Although we do not find this surprising, the fac-
tors accounting for it are unclear. One potential contribu-
tory factor that has emerged in recent studies is the marked
rise in pulmonary artery pressure that occurs during exer-
cise in older people, which increases the workload of the
right ventricle for any given cardiac output. In a review of
47 publications containing catheter data from 1187 sub-
jects, Kovacs and colleagues found that mean pulmonary
artery pressure (MPAP) at rest varied little with age,
whereas during mild exercise it increased markedly with
age (<30 years: to 18.2  5.1 mmHg; 30–50 years: to
20.0  4.7 mmHg; ≥50 years: to 29.4  8.4 mmHg
(P < 0.001)) (Kovacs et al. 2009a). Similar findings were
reported by Mahjoub and colleagues using echocardio-
graphic measurement of systolic pulmonary artery pressure
(SPAP) over the age range 20–80 years and including both
light and heavy exercise (Mahjoub et al. 2009).
An increase in pulmonary artery pressure can be attrib-
uted to an elevation in left atrial pressure at outflow from
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the lungs, an increase in the pressure drop across the pul-
monary vessels themselves (and hence pulmonary vascular
resistance), or to a combination of these two factors. A
subsequent review by Kovacs and colleagues has dissected
out these two components in 88 volunteers undergoing
catheter studies divided into four age groups (Kovacs
et al. 2012). These investigators found that pulmonary
vascular resistance was higher in older people (>70 years)
than in the youngest group (<24 years) by ~50% at all
comparable levels of CO achieved during exercise. How-
ever, the most striking contributor to an elevation in
MPAP in volunteers above 50 years of age was a large
increase in pulmonary outflow pressure, measured as pul-
monary artery wedge pressure, commonly rising to
~20 mmHg during light and heavy exercise. Of note in
view of this observation is that two studies have suggested
that older individuals also show an exaggerated pul-
monary hypertensive response to acute hypoxia at rest
(Balanos et al. 2015; Turner et al. 2015). Any strategy to
lower MPAP during exercise needs to lower pulmonary
vascular resistance, pulmonary artery wedge pressure or
both. In this study we harness previous findings to
attempt to reduce pulmonary artery pressure during exer-
cise by targeting pulmonary vascular resistance.
Three considerations are brought to bear. The first is that
exercise is associated with a marked desaturation of mixed
venous blood as oxygen extraction increases up to approxi-
mately threefold in heavy exercise (Sutton et al. 1988; Trin-
ity et al. 2012). Second, the elevation of pulmonary
vascular resistance during exposure of the lung to hypoxia
is known from many (non-human) studies to be a response
in part from a lowering of partial pressure of oxygen (PO2)
in mixed venous blood arriving at the lungs as well as the
lowering of the PO2 of alveolar gas (Marshall and Marshall
1983; Marshall et al. 1994a). Third, the sensitivity with
which this hypoxic pulmonary vasoconstriction responds
to its hypoxic stimulus has been shown in several human
studies to be ameliorated substantially by elevation of the
level of iron in the body following intravenous supplemen-
tation with iron sucrose (Talbot et al. 2014) or ferric car-
boxymaltose (Smith et al. 2008; Bart et al. 2016, 2018; Frise
et al. 2016). This sequence of connections raises the possi-
bility that iron supplementation may offer a mechanism for
reducing pulmonary vascular resistance, and therefore
right-ventricular workload, during euoxic exercise.
We hypothesized first that administration of ferric car-
boxymaltose to participants aged 50–80 years would
reduce pulmonary artery pressure during exercise, and
second that this would be reflected in an increase in max-
imal exercise capacity. We explored these hypotheses in a
prospective randomized double-blind placebo-controlled
clinical physiology study, which confirmed the first but
not the second hypothesis.
Methods
Participants
Thirty-two healthy men and women aged 50–80 years
volunteered to participate in this study. Inclusion criteria
were as follows: not a current smoker; body mass index
(BMI) <30 kg/m2; no history of severe cardiac disease,
respiratory diseases or epilepsy; receiving no iron supple-
ments or medications affecting the pulmonary circulation
during the previous 3 months; able to perform bicycling
exercise. In addition, participants were required to have
detectable tricuspid regurgitation on echocardiography for
the estimation of SPAP. At a screening visit, measure-
ments were made of forced expiratory volume in 1 sec
(FEV1), forced vital capacity (FVC), systemic arterial
blood pressure (Omron M7 Digital Blood Pressure Moni-
tor, Omron, UK), and resting consumption of oxygen
( _VO2) and elimination of carbon dioxide ( _VCO2) in a
manner described below. This study was approved by the
National Research Ethics Service Committee South Cen-
tral-Oxford B (Reference: 11/SC/0221) and was performed
in accordance with the general principles of the Declara-
tion of Helsinki. All participants provided written
informed consent.
Experimental protocol
The study design is summarized in Figure 1. In short, phys-
iological and hematological measurements were made
immediately before double-blind administration of an infu-
sion of a single dose of either ferric carboxymaltose
(15 mg/kg to a maximum of 1 g) or placebo saline, and on
five occasions in the period of 8 weeks after the administra-
tion. Participants were randomized into iron and control
groups, according to a block randomization strategy using
groups of four, with males and females in separate groups.
We aimed to induce measureable changes in iron status in
participants who were allocated ferric carboxymaltose. We
then observed in these, and their controls, SPAP and car-
diac output during light exercise, and work rate and oxygen
consumption during maximal exercise ( _VO2max).
Participants arrived in the morning around 9 AM for
the first blood sample and exercise tests. After a short
break (20–30 min), participants received an infusion over
15 min. The same tests were repeated at 3 h, 23 h,
7 days, 4 weeks, and 8 weeks after the infusion.
Echocardiographic measurement of SPAP
and cardiac output during light exercise
Light exercise was performed on a cycle ergometer (Ergo-
line Company, Germany) in the semi-supine position
2019 | Vol. 7 | Iss. 13 | e14164
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with 30–40 degrees of rotation to the left. The exercise
protocol included 5 min of rest, 20 min of exercise, and
5 min of a resting recovery phase. SPAP was estimated
using measurements of peak systolic tricuspid regurgitant
jet velocity (VTR), obtained from an apical 4-chamber
view of the heart using continuous wave Doppler, as
4VTR
2 + 5 mmHg (Rudski et al. 2010) at rest and during
a level of exercise that increased the heart rate to 30 bpm
above the resting value, an increase known to be associ-
ated with 50% of maximum oxygen consumption (Herig-
stad et al. 2007). Cardiac output was measured using
standard techniques by visualizing the left-ventricular out-
flow tract via an apical 5-chamber view of the heart, and
integrating the outflow velocity from pulsed-wave Dop-
pler with respect to time over several heartbeats (Balanos
et al. 2005; Talbot et al. 2005). The left-ventricular out-
flow tract diameter was estimated from a parasternal
long-axis view. The baseline values of echocardiographic
measurement were determined as the averaged echocar-
diographic data over the resting period. The exercise val-
ues of echocardiographic measurement were determined
as the averaged echocardiographic data over the second
half of the exercise period.
Measurement of _VO2max during an
incremental exercise test
The incremental exercise test was performed on a cycle
ergometer (KEM-3, CardioKinetics. Limited, UK) with a
face mask (Metro SealTM 7900 Adult Face mask, Hans
Rudolph Inc., USA) to determine _VO2max and maximum
work rate using a metabolic measurement system (Jae-
gerTM Oxycon, Carefusion, UK). The exercise protocol
was adapted from that described by Rossiter et al. (2006).
Each participant performed a standard incremental exer-
cise test to the point of volitional exhaustion with the
work rate rising incrementally at 15 W per minute, from
0 W. At the point of exhaustion, participants were asked
to continue pedaling at 0 W for a further 5 min, after
which the work rate was increased abruptly to a value
105% of the maximum work rate achieved during the
incremental test. The participant was again asked to pedal
to exhaustion. During both phases of the protocol,
exhaustion was determined by participants stopping or by
the cadence falling below 60 rpm. The _VO2max was
determined as the average of _VO2 values over 15 sec dur-
ing the period of maximum _VO2 during the exercise test.
If the highest _VO2 values achieved differed between the
two exhaustion periods, the higher value was taken to
represent the participant’s _VO2max. Baseline _VO2 and _VCO2
were taken as the average of measurements from the 2nd
minute on the ergometer before pedaling commenced.
Peripheral oxyhemoglobin saturation (SpO2) was mea-
sured using a pulse oximeter (Ohmeda Biox 3740 Pulse
Oximeter, BOC Healthcare, UK) with a finger probe
(OXY-F4-H finger sensor, GE Healthcare, UK).
Infusion of ferric carboxymaltose or control
saline
The infusion procedure was double-blind: volunteers
wore eye masks during infusions, which were adminis-
tered by physicians not involved in data analysis. Each
participant in the iron group received 15 mg/kg of iron
(up to a maximum dose of 1000 mg) as ferric carboxy-
maltose (Ferinject, Vifor Pharma) diluted to 50 mL with
0.9% NaCl. The control infusion consisted of 50 mL
0.9% NaCl. The infusion time was 15 min and controlled
by a syringe pump (GrasebyTM 3100 Syringe Pump,
Smith Medical International Ltd, UK).
Blood samples and analytical procedures
Venous blood samples were obtained from a forearm vein
for assay of hemoglobin (Hb), hematocrit (Hct), mean
cell volume (MCV), serum iron, serum ferritin, serum
transferrin, transferrin saturation, plasma hepcidin, and
plasma C-reactive protein (CRP). Blood was distributed
into tubes containing EDTA (EDTA BD Vacutainer,
BD) or micronized silica particles (SST BD Vacutainer,
BD) for immediate hematology and biochemistry analysis;
plasma was prepared by centrifugation at 3000g and
immediately frozen at –80°C for later analysis of hepcidin
by enzyme-linked immunosorbent assay (ELISA, Hep-
cidin-25 human- EIA Kit, Bachem). The ELISA analysis
was in duplicate and followed the guidelines of the manu-
facturer.
If a participant’s CRP was elevated above the normal
range for the assay (>8 mg/L), hematological indices from
that visit were excluded from analysis in case there was
Figure 1. Schematic diagram of time course of the protocols. Blood: blood samples; EC: echocardiography at rest and during light cycle
exercise; EX: _VO2max exercise. Infusion refers to the blinded administration of either ferric carboxymaltose or saline. For further details see text.
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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an intercurrent mild inflammatory illness that might have
temporarily disturbed iron homeostasis (Feelders et al.,
1998; Gabay and Kushner, 1999; Ganz, 2003).
Statistical analysis
Between-groups comparisons of participant characteristics
were performed using a two-tailed Student’s t-test. To
assess changes in blood and iron indices and changes in
hemodynamic variables after infusion, a two-way repeated
measures analysis of variance (ANOVA), using time and
group as factors, was performed using SigmaPlot (Version
12.0, Systat Software). The Bonferroni procedure was
used in post hoc analysis to perform the multiple com-
parison. Results are given as mean  SEM if not other-
wise stated.
To assess the effect of iron infusion on SPAP, _VO2max
and maximum work rate, results were analysed using lin-
ear mixed effects modeling (SPSS version 23), with the
model structures as indicated in the Results section. In all
cases, P less than 0.05 was taken to be statistically signifi-
cant.
Results
Participant characteristics
The characteristics of enrolled participants are shown in
Table 1. There was no significant difference between
groups with regard to these characteristics. The infusions
were well tolerated with no severe adverse reactions or
withdrawals. Two participants (one in each group) expe-
rienced headache after the infusion and one participant
from the iron group reported a fever the day after the
infusion.
Iron status indicators and hematological
variables
At baseline, the iron and the placebo groups had similar
iron status as indicated by concentrations of serum iron,
serum ferritin, serum transferrin, transferrin saturation,
and plasma hepcidin (Fig. 2). After the infusion, a rapid
significant increase in serum iron was seen in the iron
group. The highest iron concentration was reached at 4 h
and dropped to reach the control value 4 weeks after the
infusion (Fig. 2A). The ferritin and hepcidin concentra-
tions following iron infusion rose substantially, respec-
tively, by 23 and 4 h, and stayed significantly raised
throughout the 8 weeks (Fig. 2B and E). The transferrin
concentration in the iron group fell by 23 h and
remained low for the 8-week period (Fig. 2C). Transferrin
saturation followed the pattern of change of serum iron
(Fig. 2D), values above 100% indicating short-term pres-
ence of free iron in plasma and/or iron bound to species
other than transferrin (Zanen et al. 1996). In contrast,
concentrations of iron, ferritin, transferrin, transferrin sat-
uration, and hepcidin in the control group remained
unchanged. These data show that iron was successfully
delivered to the circulation and led to a long-term rise in
ferritin concentration consistent with the dosage adminis-
tered (Bart et al. 2018).
On ten occasions (iron group 7; placebo group 3),
CRP exceeded 8 mg/L and laboratory blood-test data for
these time points were excluded from the analysis. A sen-
sitivity analysis exploring the effect of including these data
found no significant alteration to the reported findings.
At baseline, the iron and the placebo groups showed
no significant difference with regard to hemoglobin con-
centration (Fig. 2F), Hct, or MCV. No significant changes
were seen in hemoglobin concentration in either group
throughout the 8 weeks (Fig. 2F). No significant changes
in Hct or MCV were seen at any time point following
iron or saline infusion.
Cardiovascular variables at rest and during
light exercise
At baseline, in the resting condition, no significant differ-
ences were measured between the iron and placebo
groups with respect to any cardiovascular variable.
Figure 3 shows the time-course of SPAP and heart
rate over 30 min for a typical volunteer undergoing the
moderate exercise protocol. This protocol stipulated a
rise in heart rate of 30 bpm from rest to light exercise.
An analysis of the mean heart rate achieved over all time
points showed close compliance with the protocol in
both groups (change in the iron group 29.0  0.3 bpm;
Table 1. Participant characteristics. Values are shown as
mean  SD
Iron group Control group
Number, n 16 16
Sex, %male 50% 50%
Age, year 65.4  8.6 64.6  4.9
Height, cm 167.5  10.1 168.0  8.5
Weight, kg 67.3  14.8 67.9  11.0
FEV1, % predicted 108.1  17.1 107.1  16.9
FVC, % predicted 117.6  16.5 111.9  14.0
FEV1/FVC 74.2  8.8 76.2  6.0
Systolic blood pressure, mmHg 124.4  13.7 121.6  15.4
Diastolic blood pressure, mmHg 80.0  8.3 81.9  10.9
Baseline _VO2, mL/min 299  18 308  17
Baseline _VCO2, mL/min 239  17 239  12
2019 | Vol. 7 | Iss. 13 | e14164
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change in the placebo group 28.5  0.6 bpm
(P = 0.46)). Table 2 presents cardiac output and SPAP
pre-infusion and at five times in the 8-week period fol-
lowing infusion. At baseline, during exercise, as during
rest, no significant differences were measured between
the iron and saline groups with respect to any cardiovas-
cular variable.
Figure 4 shows SPAP at rest and during moderate exer-
cise for the group receiving iron and the controls. Linear
mixed effects modeling on the postinfusion data using the
Figure 2. Iron indices and hemoglobin concentration. A. Serum iron concentration; B. Serum ferritin concentration; C Serum transferrin
concentration; D Transferrin saturation; E. Plasma hepcidin concentration; F. Hemoglobin (Hb) concentration. Empty circles represent data
before infusions and the control group throughout. Filled circles represent data following iron administration in the iron group. Values are
mean  SEM.
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2019 | Vol. 7 | Iss. 13 | e14164
Page 5
H.-Y. Cheng et al. Iron and Pulmonary Artery Pressure During Exercise
preinfusion pressure as a covariate and with fixed factors
of treatment (iron vs. saline) and exercise-by-treatment
revealed a significant effect of exercise-by-treatment
(P < 0.0001). Successive data points for each subject were
treated as repeated measures. Subgroup analysis on the
rest and exercise data separately revealed that treatment
had a significant effect only on the exercise data. It is
notable from Figure 4 that the effect of iron during exer-
cise persisted for the whole of the 8-week period. Figure 5
shows the individual changes in SPAP at rest and during
exercise from the pre-infusion values to the 8-week values
normalized to be zero mid-experiment. In those receiving
iron, each individual participant showed a decline in exer-
cise SPAP during this period. No consistent change
occurred at rest in those receiving iron. In the control
group, no consistent change is seen, either at rest or dur-
ing exercise, during this period of 8 weeks.
_VO2max, work rate, and SpO2 during the
incremental exercise test
Figure 6 shows measurements of oxygen consumption
and work rate for a typical volunteer during the incre-
mental exercise test. The responses to heavy exercise dur-
ing the incremental exercise tests are shown in Figure 7.
Linear mixed effects modeling on the postinfusion data
using the preinfusion values as covariates and with treat-
ment (iron vs. saline) as a factor found no significant
effect of iron administration on either _VO2max or work
rate. Successive data points for each subject were treated
as repeated measures. Values for peripheral
oxyhemoglobin saturation, SpO2, at rest and during max-
imal exercise are also shown in Figure 7. No differences
between groups, and no changes from baseline, were
observed. Maximal exercise was associated at all times
with a fall in SpO2 of approximately 1.5–2.0%.
Discussion
The main finding of this study is that intravenous iron
supplementation in older healthy humans leads to a sus-
tained attenuation of the pulmonary artery pressure dur-
ing moderate air-breathing (euoxic) exercise. This effect
persisted for 8 weeks. We interpret these findings in the
context of (1) considering whether the fall in the PO2 of
venous blood during exercise might act as a stimulus to
“hypoxic pulmonary vasoconstriction” even though air-
breathing exercise is usually not regarded as a form of
hypoxia; (2) studies finding that administration of
vasodilators can reduce pulmonary artery pressure during
exercise in hypoxia; (3) observations showing a reduction
in hypoxic pulmonary vasoconstriction in humans at rest,
induced by administration of iron; and (4) the finding
that iron administration can enhance exercise capacity in
heart failure. These are discussed in turn below.
The extent to which euoxic exercise may be
regarded as a stimulus for “hypoxic
pulmonary vasoconstriction”
Alveolar and systemic arterial levels of oxygenation com-
monly remain largely unchanged during exercise, as
Figure 3. Acquisition of echocardiographic data during a light cycle exercise test from a representative participant. The participant rested on
the ergometer for 5 min and then started exercise aiming to reach a target heart rate of 30 bpm above resting heart rate (empty triangles).
Exercise was sustained for 20 min and the participant was then allowed to rest. Systolic pulmonary artery pressure (SPAP, black circles) was
measured for the whole duration. Data obtained from first 5 min were averaged and taken as the resting value. Data between 16th and 25th
minute were averaged and taken as the exercise value.
2019 | Vol. 7 | Iss. 13 | e14164
Page 6
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Iron and Pulmonary Artery Pressure During Exercise H.-Y. Cheng et al.
ventilation keeps pace with the elevation in metabolic
rate. Mixed venous blood arriving at the lungs, however,
is increasingly desaturated as exercise intensity increases
(Trinity et al. 2012). Thus, for example, a high work rate
in volunteers exercising at sea level was associated with a
mixed-venous PO2 below 20 mmHg (Sutton et al. 1988).
Studies, using relatively brief experiments in nonhuman
species at rest have shown that the stimulus PO2 (PSO2)
for hypoxic pulmonary vasoconstriction may commonly
be regarded as a function of both alveolar PO2 (PAO2) and
mixed-venous PO2 (PVO2) according to the following
relationship (Marshall and Marshall 1983; Marshall et al.
1994a):
PSO2 ¼ P0:6AO2  P0:4VO2
Interestingly, no study has confirmed this behavior for
the human lung, and yet models of human hypoxic pul-
monary vasoconstriction have been structured assuming
that it is appropriate in humans in health (Marshall et al.
1994c) and disease (Marshall et al. 1994b). Since PVO2
falls during exercise, the above equation suggests that
exercise may expose the lung to a sufficient reduction in
PSO2 to activate hypoxic pulmonary vasoconstriction. We
explore below what consequences this activation of some-
thing usually associated with hypoxic exposure might
have if it is actually occurring during euoxic exercise.
Studies directed at lowering pulmonary
artery pressure during exercise in hypoxia
Several studies have addressed the hypotheses that pul-
monary artery pressure during exercise can be lowered by
pulmonary vasodilators, and that this can lead to an
increase in cardiac output and in exercise capacity. In
2004, Ghofrani et al. showed that sildenafil reduced pul-
monary artery pressure, and increased cardiac output and
peak work rate, both whilst volunteers at low altitude
breathed 10% oxygen and whilst at Everest Base Camp at
an altitude of 5400 m (Ghofrani et al. 2004). Their volun-
teers had a median age of 36.5 years. Using another phos-
phodiesterase-5 inhibitor, tadalafil, Fischler et al. were
unable to show similar changes at low and high (4559 m)
altitude in adults known to have particularly vigorous
hypoxic pulmonary vasoconstriction, but did find that
dexamethasone increased _VO2max significantly, a rise that
was associated with a strong trend toward an increase in
peak work rate and a lower pulmonary artery pressure
(Fischler et al. 2009). Their group had a mean age of
Table 2. Hemodynamic data preinfusion and at five times in the 8-week period following infusion. Values are shown as mean  SEM
Preinfusion 3 h 23 h 7 days 4 weeks 8 weeks
CO at rest with placebo, L/min 4.46  0.15 5.06  0.22## 4.93  0.13# 4.80  0.14 5.07  0.23## 4.70  0.15
CO in exercise with placebo, L/min 7.60  0.19 8.09  0.24 7.75  0.18 7.70  0.21 7.73  0.26 7.99  0.18
CO at rest with iron, L/min 4.48  0.20 4.85  0.23 4.76  0.22 4.99  0.20** 4.71  0.21 4.82  0.16
CO in exercise with iron, L/min 7.65  0.31 7.90  0.32 7.94  0.34 7.94  0.31 7.90  0.28 7.96  0.25
SPAP at rest with placebo, mmHg 24.8  1.0 25.0  0.9 25.0  1.0 24.9  1.00 25.5  0.9 24.7  0.9
SPAP in exercise with placebo, mmHg 38.9  1.8 39.0  1.7 38.9  1.9 38.8  1.9 39.0  1.7 38.5  1.8
SPAP at rest with iron, mmHg 23.0  0.7 22.9  0.7 23.5  0.7 23.4  0.8 23.3  0.6 22.7  0.7
SPAP in exercise with iron, mmHg 39.4  1.0 38.6  0.9 37.2  0.9*** 37.1  1.0*** 37.2  0.9*** 36.9  0.9***
Different from the preinfusion measurement in the placebo group: #P < 0.05, ##P < 0.01.
Different from the preinfusion measurement in the iron group: **P < 0.01, ***P < 0.001.
Figure 4. Systolic pulmonary artery pressure (SPAP) at rest and
during moderate exercise. Empty circles represent data before
infusions and the control group throughout. Filled circles represent
data following iron administration in the iron group. Values are
mean  SEM. Iron administration lowers SPAP significantly during
exercise (P < 0.0001) but not at rest.
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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44 years. The authors questioned whether their tadalafil
dosing had been adequate. The effect of dexamethasone
they observe on _VO2max may be associated with its action
as a marked stimulant of ventilation (Liu et al. 2013).
Further studies showing no effect of phosphodiesterase-5
inhibition (using sildenafil) on maximal exercise capacity
in acute hypoxia include one at 4000 m equivalent exam-
ining volunteers with a mean age 26.8 years (Toro-Salinas
et al. 2016) and another one at 2750 m equivalent
recruiting older volunteers with a mean age of 66.5 years
(Rodway et al. 2016).
Another approach to lowering right ventricular after-
load and increasing exercise capacity in hypoxia has been
the use of endothelin receptor inhibition. In acute
hypoxia (12% oxygen at sea level) in participants with
mean age 29 years, it was reported that the nonselective
inhibitor bosentan lowered pulmonary artery pressure
and significantly increased maximum work-rate and
_VO2max (Faoro et al. 2009). The Brussels research group
went on to assess the effects of the endothelin receptor-A
antagonist sitaxentan both during acute hypoxia (12%
oxygen at sea level) and at 5050 m in Nepal, in a group
with mean age 35 years (Naeije et al. 2010). Again, both
workload and _VO2max were significantly increased by the
agents and these changes were related to reductions in
right ventricular afterload.
There appears, therefore, to be some evidence that pul-
monary vasodilatation during hypoxia can increase exer-
cise capacity possibly by increasing cardiac output.
Results may depend upon the degree of hypoxia, agent,
dosing, and the age of those studied. Interestingly, we
remain uncertain regarding the way in which hypoxic
pulmonary vasoconstriction might act to limit cardiac
output during exercise. By introducing an increased resis-
tance between the right and left sides of the heart, its
action could be via the associated increase in right-ven-
tricular afterload, via a reduction in the left-ventricular
preload, or a combination of the two. Data suggesting
that a reduction in left-ventricular preload during hypoxic
exercise may be an important factor limiting exercise
capacity come from the Operation Everest II study, in
which eight volunteers spent 40 days in a decompression
Figure 5. Individual changes in systolic pulmonary artery pressure (DSPAP) at rest and during exercise from the preinfusion values (0 w) to the
8-week values (8 w) normalized to be zero mid experiment. In those receiving iron, each individual participant showed a decline in exercise
SPAP during this period. No consistent change occurred in the three other conditions.
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Figure 6. Incremental exercise test protocol and measurement from a representative participant. Maximal oxygen consumption was
determined as the average of oxygen consumption values over a 15-sec interval during the period of volitional exhaustion. The higher value
between the two exhaustion periods was chosen, indicated in this case by an arrow. Resting oxygen consumption and carbon dioxide
elimination were determined by the average of the 2nd minute period (bar close to the origin).
Figure 7. Measurements of maximal oxygen consumption, _VO2max, (A), peak work rate (B), and peripheral oxyhemoglobin saturation, SpO2, (C)
preinfusion (open symbols for both groups) and after infusion for controls (open symbols) and iron group (closed circles). Values of SpO2 are
given at rest and during maximal exercise. Values are mean  SEM and did not differ significantly between groups.
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chamber, in which the pressure was gradually reduced
from a “sea-level” value to that at the summit of Mount
Everest (Reeves et al. 1987). Large rises in right-ventricu-
lar afterload were demonstrated by pulmonary artery
catheterization at rest and during exercise as the decom-
pression intensified. The study also showed lower filling
pressures of the left ventricle during exercise in hypoxia
compared with euoxia. In the “sea-level” conditions, left
atrial pressures rose from 6.9 mmHg at rest to
16.4 mmHg at maximum cardiac output. With exercise at
“higher altitudes”, the left atrial pressure was found not
to rise with exercise above the values at rest (still around
7 mmHg), revealing a contractile ventricle with an output
probably limited by poor filling (Reeves et al. 1987).
The studies discussed in this section relate to exercise
in hypoxia, either during the breathing of a low percent-
age of oxygen near sea level, or whilst at altitude. This
study was conducted during air-breathing near sea level.
We have shown in the preceding section that the stimulus
PO2 for pulmonary vasoconstriction may be a function of
both alveolar and mixed-venous PO2 values, and that con-
sequently experiments conducted during hypoxic expo-
sure may have a bearing on the euoxic exercise reported
here.
Studies showing a reduction in hypoxic
pulmonary vasoconstriction at rest
following iron administration
Without having an effect on pulmonary artery pressure in
euoxia, an acute infusion of iron has been shown to abol-
ish the slow phase of human hypoxic pulmonary vaso-
constriction that develops over 1–8 h of exposure to
isocapnic hypoxia at rest (Talbot et al. 2014) and mark-
edly obtund the rise in the acute sensitivity of the pul-
monary vasculature to hypoxia (the fast phase of hypoxic
pulmonary vasoconstriction) that occurs following such
an 8-h exposure to hypoxia (Smith et al. 2008). Corre-
spondingly, clinical iron deficiency is associated with an
enhanced hypoxic pulmonary vasoconstriction response
that can be ameliorated by iron infusion (Frise et al.
2016). These studies all suggest that iron supplementation
only reduces hypoxic pulmonary vasoconstriction when
there is a “priming” period of hypoxia of more than an
hour in duration before the effects of iron on hypoxic
pulmonary vasoconstriction are measured. This is consis-
tent with the hypothesis that it is transcriptional regula-
tion by the hypoxia-inducible factor (HIF) pathway that
is being manipulated by administering iron, and that this
takes time to take effect (Smith et al. 2006, 2008). What
remains uncertain is whether a pulmonary vascular
response to the lowering of PO2 in mixed-venous blood
during euoxic exercise can be attenuated by administering
iron.
In this study, exercise was performed for relatively
short periods of time not exceeding 1 h, and therefore a
salient question is whether iron status can affect pul-
monary vascular responses to periods of desaturation of
mixed-venous blood lasting less than 1 h. The human
pulmonary vascular response to eucapnic alveolar hypoxia
in people at rest starts with an abrupt acute vasoconstric-
tion (a fast phase) occurring over a few (~5) minutes. If
the hypoxia is maintained, this constriction begins to
intensify after about 40 min (Talbot et al. 2005), and
continues to increase over the periods of 2–8 h (a slow
phase) that have been studied in various laboratory pro-
tocols (Dorrington et al. 1997; Balanos et al. 2002; Talbot
et al. 2014). Prior infusion of iron has not been found to
change the magnitude of the fast phase, often measured
at ~1 h, but does have a marked effect in diminishing or
abolishing the subsequent slow phase, over 2–8 h (Talbot
et al. 2014; Bart et al. 2016; Frise et al. 2016). This blunt-
ing of the slow phase of hypoxic pulmonary vasoconstric-
tion has now been shown to persist for at least as long as
43 days after a single infusion of iron, with the 1-h fast-
phase response remaining unaffected throughout this per-
iod (Bart et al. 2016).
The accumulated evidence therefore suggests that prior
iron administration in the resting individual has the capa-
bility to (1) reduce the slow phase of hypoxic pulmonary
vasoconstriction and (2) reduce the exaggeration of the
fast phase of hypoxic pulmonary vasoconstriction that is
induced by priming with a sustained period (~8 h) of
hypoxia. We lack evidence that iron administration can
influence the fast phase of hypoxic pulmonary vasocon-
striction unless this priming takes place.
Possible explanations for the finding of a
reduced SPAP during exercise following iron
The observation in this study (Fig. 4) that SPAP during
exercise is decreased from 3 h following an iron infusion
may therefore provide evidence that: (1) the model repre-
sented by the above equation for PSO2 is valid for
humans, (2) the intermittent lowering of mixed-venous
PO2 in small bouts of exercise occurring in normal daily
life constitute a cumulative priming stimulus for the pul-
monary vasculature yielding: (3) a reduction in an acute
pulmonary vascular response to a brief (20-min) bout of
exercise in those volunteers who received iron. If there is
no sensitivity of the human pulmonary vasculature to a
lowering of PVO2 of the sort expressed in the equation, it
is difficult to understand why iron has the capacity to
reduce the rise in SPAP occurring during exercise.
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An alternative explanation could be that improved left-
ventricular function following iron administration could
permit the same level of exercise with a lower left-sided
preload. If that is the case, a fall in filling pressure of
~3 mmHg would represent a substantial change in ino-
tropic state.
Enhancement of exercise capacity following
iron administration in patients with
cardiopulmonary disease
The administration of intravenous iron to nonanemic
iron-deficient patients with heart failure has been found
to lead to an improvement in exercise capacity measured
by the 6-min walk test in two similar studies over
6 months (Anker et al. 2009) and 12 months (Ponikowski
et al. 2015). Similar results have emerged from studies on
patients with pulmonary arterial hypertension (Viethen
et al. 2014; Ruiter et al. 2015). One possible contributory
mechanism is the finding that iron deficiency is associated
with much more marked hypoxic pulmonary vasocon-
striction, and that this abnormality can be corrected by
administration of intravenous iron (Frise et al. 2016).
Cardiopulmonary measurements in exercise were not
obtained in the heart-failure and pulmonary arterial
hypertension studies, so we remain ignorant of whether a
reduction in right ventricular afterload or an increase in
left ventricular preload may have assisted walking in the
exercise tests. This study was conducted in iron-replete
healthy participants of a similar age; nevertheless its find-
ing of a reduction in pulmonary artery pressure during
moderate cycling exercise tentatively suggests a mecha-
nism whereby exercise capacity may have been improved
in the patients in clinical studies. If this turns out to be
the case, it would be analogous to the enhancement of
exercise achieved in some studies of healthy human vol-
unteers exposed to hypoxia, such as that using sildenafil
at Everest Base Camp (Ghofrani et al. 2004). It may be
the case that, whilst the small fall in pulmonary artery
pressure measured in this study has no impact on maxi-
mal exercise capacity in our healthy volunteers, it could
be sufficient to affect exercise capacity in a patient with
impaired myocardial function.
As noted earlier, another possible mechanism whereby
pulmonary artery pressure is lowered in exercise by iron
supplementation is an improvement in left ventricular
function. Such an effect was suggested by a study of
patients with heart failure and iron deficiency in the set-
ting of chronic renal failure (Toblli et al. 2015). This
could lead to a lowering of left-sided filling pressure for
the same level of cardiac output. This would result in a
lower pulmonary artery pressure without any change in
the pressure drop across the pulmonary circulation.
Conclusions
Iron administration appears to act as a pulmonary
vasodilator selectively during exercise in the older healthy
human. The effect is maintained over many weeks after
a single dose of iron. A body of literature links this
observation with the inhibition by iron of vasoconstric-
tion in the lung, via the HIF transcription factor path-
way. Elevated SPAP can be implicated as a factor
limiting exercise capacity, particularly in the aging popu-
lation (Kovacs et al. 2009a), and in those with underly-
ing lung or connective tissue disease (Kovacs et al.
2009b). Iron has already been shown to improve exercise
tolerance in patients with heart failure (Anker et al.
2009), and this may be due to effects on the pulmonary
vasculature.
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